TY - JOUR AU - Grassi, Paolo AU - Verzoni, Elena AU - Mennitto, Alessia AU - Procopio, Giuseppe PY - 2016 TI - Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice JF - Translational Andrology and Urology; Vol 5, No 6 (December 18, 2016): Translational Andrology and Urology (Testosterone Replacement Therapy) Y2 - 2016 KW - N2 - Final results from the randomised phase III METEOR study have been recently published and confirmed the superiority of cabozantinib over everolimus in patients with advanced or metastatic clear-cell renal cell carcinoma (mRCC) who received at least one previous VEGFR tyrosine-kinase inhibitor (TKI) (1). UR - https://tau.amegroups.org/article/view/12807